Skip to Main Content

Sarepta Therapeutics said Monday that its gene therapy improved muscle function for a group of patients with Duchenne muscular dystrophy — updated results from a mid-stage study the company believes ameliorates an initial negative outcome last year and might support accelerated approval.

But the magnitude of the benefit shown by Sarepta’s one-time treatment was lower than some investors hoped to see. That concern, coupled with weaker financial guidance for the year, caused Sarepta’s stock price to drop.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment